MYND Life Sciences Inc. (MYNDF)
USD 0.06
(0.0%)
USD 0.06
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.58 Million CAD | -44.9% |
| 2022 | 2.88 Million CAD | -32.82% |
| 2021 | 4.29 Million CAD | 7500.29% |
| 2020 | 56.46 Thousand CAD | 2127.46% |
| 2019 | 2535.00 CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 281.77 Thousand CAD | 113.32% |
| 2024 Q2 | 132.09 Thousand CAD | -51.87% |
| 2024 Q1 | 274.43 Thousand CAD | -16.47% |
| 2023 Q4 | 328.54 Thousand CAD | 29.12% |
| 2023 FY | 1.58 Million CAD | -44.9% |
| 2023 Q3 | 254.44 Thousand CAD | -39.44% |
| 2023 Q2 | 420.13 Thousand CAD | -28.26% |
| 2023 Q1 | 585.64 Thousand CAD | 30.67% |
| 2022 Q2 | 717.23 Thousand CAD | -38.31% |
| 2022 Q1 | 1.16 Million CAD | -19.81% |
| 2022 FY | 2.88 Million CAD | -32.82% |
| 2022 Q4 | 448.19 Thousand CAD | -20.36% |
| 2022 Q3 | 562.74 Thousand CAD | -21.54% |
| 2021 Q2 | 762.42 Thousand CAD | -35.39% |
| 2021 Q4 | 1.44 Million CAD | 61.23% |
| 2021 Q3 | 899.27 Thousand CAD | 17.95% |
| 2021 FY | 4.29 Million CAD | 7500.29% |
| 2021 Q1 | 1.18 Million CAD | 0.0% |
| 2020 FY | 56.46 Thousand CAD | 2127.46% |
| 2019 FY | 2535.00 CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.169% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 67.694% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.144% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 94.624% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 95.736% |
| Mesoblast Limited | 5.9 Million USD | 73.081% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -5.784% |
| Genus plc | 147.7 Million USD | 98.924% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 81.903% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -18.428% |
| Marizyme, Inc. | 19.23 Million USD | 91.742% |
| ContraFect Corporation | 56.88 Million USD | 97.207% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 80.948% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 63.963% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -7.439% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 45.52% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 43.062% |
| MultiCell Technologies, Inc. | 567.42 USD | -279897.709% |
| Accustem Sciences Inc. | 3.74 Million USD | 57.592% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.151% |
| EV Biologics, Inc. | 531.96 Thousand USD | -198.661% |
| Q BioMed Inc. | 3.43 Million USD | 53.77% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 93.572% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -307.829% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 39.534% |
| Biomind Labs Inc. | 994.18 Thousand USD | -59.806% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 99.295% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 76.351% |
| Skye Bioscience, Inc. | 13.54 Million USD | 88.273% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 22.45% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 6455.052% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 68.49% |
| IMV Inc. | 37.7 Million USD | 95.787% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 90.077% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 13.423% |
| GB Sciences, Inc. | 1.42 Million USD | -11.845% |
| Alpha Cognition Inc. | 9.7 Million USD | 83.63% |
| HST Global, Inc. | 140.9 Thousand USD | -1027.526% |
| CSL Limited | 3.44 Billion USD | 99.954% |
| Halberd Corporation | 74.84 Thousand USD | -2022.823% |
| Enzolytics Inc. | 2.17 Million USD | 27.104% |
| Resverlogix Corp. | 12.71 Million USD | 87.502% |
| Affymax, Inc. | 39.38 Million USD | 95.966% |
| SYBLEU INC | 160.87 Thousand USD | -887.57% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 56.481% |
| argenx SE | 1.53 Billion USD | 99.896% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 97.234% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -52.18% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -0.596% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 53.34% |
| AVAX Technologies, Inc. | 7.31 Million USD | 78.267% |
| Zenith Capital Corp. | 8.94 Million USD | 82.235% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.808% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -9019.815% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 35.293% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -826.344% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.401% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 9.713% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | 19.435% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 14.783% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 85.38% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 17.291% |
| BioStem Technologies, Inc. | 22.97 Million USD | 93.085% |
| ONE Bio Corp. | 6.44 Million USD | 75.345% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -775.424% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -18.97% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -41.235% |
| Agentix Corp. | 1.37 Million USD | -15.82% |
| LadRx Corporation | 3.81 Million USD | 58.32% |
| Cell Source, Inc. | 4.32 Million USD | 63.269% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -282.393% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -72.035% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -72.035% |
| NovAccess Global Inc. | 2.46 Million USD | 35.593% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 33.937% |
| Itoco Inc. | 919.14 Thousand USD | -72.853% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 62.515% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -41.981% |
| Kadimastem Ltd | 2.41 Million USD | 34.079% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -507.033% |
| CytoDyn Inc. | 18.05 Million USD | 91.202% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -6212.38% |
| Mobile Lads Corp. | 554.54 Thousand USD | -186.498% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -621.909% |
| Qrons Inc. | 643.67 Thousand USD | -146.826% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -11.901% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | 28.751% |
| Rebus Holdings, Inc. | 664 Thousand USD | -139.272% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 12.528% |
| International Stem Cell Corporation | 5.27 Million USD | 69.858% |
| Bioxytran, Inc. | 3.82 Million USD | 58.411% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -2918.052% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -7709.876% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 95.619% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 1.807% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -115.913% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 48.931% |
| Neutra Corp. | 243.82 Thousand USD | -551.61% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 90.899% |
| PureTech Health plc | 144.59 Million USD | 98.901% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 92.246% |
| IXICO plc | 4.7 Million USD | 66.247% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 81.94% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.651% |
| CSL Limited | 3.89 Billion USD | 99.959% |
| Cellectis S.A. | 97.32 Million USD | 98.367% |